Libevitug - Huahui Health
Alternative Names: HH-003Latest Information Update: 28 Oct 2025
At a glance
- Originator Huahui Health
- Class Antiretrovirals; Antivirals; Monoclonal antibodies
- Mechanism of Action Hepatitis B surface antigen presurface protein 1 inhibitors; Sodium bile acid cotransporter expression inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for phase-I development in Hepatitis-B(Treatment-naive, In adults) in China (IV, Injection)
- 21 Jun 2025 Huahui Health completes a phase II trial in Hepatitis D (Treatment-experienced) in China (IV) (NCT05861674)
- 21 Nov 2024 HH 003 receives Breakthrough Therapy status for Hepatitis D in USA